The Renin-Angiotensin and Renal Dopaminergic Systems Interact in Normotensive Humans

Journal of the American Society of Nephrology

Volumn 27, Issue 1, 2016, Pages 265-279

  Natarajan, Aruna R ^a   Eisner, Gilbert M ^a   Armando, Ines ^b   Browning, Shaunagh ^d   Pezzullo, John C ^d   Rhee, Lauren ^d   Dajani, Mustafa ^a   Carey, Robert M ^e   Jose, Pedro A ^a,c  

^a GEORGETOWN UNIVERSITY HOSPITAL   (United States)

^b Division of Nephrology   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOHIPPURIC ACID; DIPEPTIDYL CARBOXYPEPTIDASE; DOPAMINE 1 RECEPTOR; ENALAPRIL; FENOLDOPAM; LITHIUM; POTASSIUM; SODIUM; SODIUM CHLORIDE; DOPAMINE RECEPTOR;

ADULT; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; CROSSOVER PROCEDURE; DOPAMINERGIC SYSTEM; DOUBLE BLIND PROCEDURE; ENZYME INHIBITION; FEMALE; HEMODYNAMIC PARAMETERS; HUMAN; HUMAN EXPERIMENT; KIDNEY DISTAL TUBULE; KIDNEY PROXIMAL TUBULE; LOW DRUG DOSE; MALE; MICTURITION; NATRIURESIS; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SODIUM BALANCE; SODIUM LOAD; SODIUM RESTRICTION; SODIUM TRANSPORT; SODIUM URINE LEVEL; BLOOD PRESSURE; KIDNEY; METABOLISM; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL;

ADULT; BLOOD PRESSURE; CROSS-OVER STUDIES; DIET, SODIUM-RESTRICTED; DOUBLE-BLIND METHOD; FEMALE; HUMANS; KIDNEY; MALE; RECEPTORS, DOPAMINE; RENIN-ANGIOTENSIN SYSTEM;

EID: 84954446610     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2014100958     Document Type: Article

References (70)

1. DiBona GF, Esler M: Translational medicine: The antihypertensive effect of renal denervation. Am J Physiol Regul Integr Comp Physiol 298: R245-R253, 2010
2. Osborn JW, Fink GD, Kuroki MT: Neural mechanisms of angiotensin II-salt hypertension: Implications for therapies targeting neural control of the splanchnic circulation. Curr Hypertens Rep 13: 221-228, 2011
3. Navar LG, Nishiyama A: Why are angiotensin concentrations so high in the kidney? Curr Opin Nephrol Hypertens 13: 107-115, 2004
4. Gavras I, Gavras H: 'Volume-expanded' hypertension: The effect of fluid overload and the role of the sympathetic nervous system in saltdependent hypertension. J Hypertens 30: 655-659, 2012
5. Hall JE, Granger JP, do Carmo JM, da Silva AA, Dubinion J, George E, Hamza S, Speed J, Hall ME: Hypertension: Physiology and pathophysiology. Compr Physiol 2: 2393-2442, 2012
6. Cao YN, Kitamura K, Kato J, Kuwasako K, Ito K, Onitsuka H, Nagoshi Y, Uemura T, Kita T, Eto T: Chronic salt loading upregulates expression of adrenomedullin and its receptors in adrenal glands and kidneys of the rat. Hypertension 42: 369-372, 2003
7. Ferrario CM, Jessup J, Gallagher PE, Averill DB, Brosnihan KB, Ann Tallant E, Smith RD, Chappell MC: Effects of renin-angiotensin system blockade on renal angiotensin-(1-7) forming enzymes and receptors. Kidney Int 68: 2189-2196, 2005
8. Padia SH, Kemp BA, Howell NL, Fournie-ZaluskiMC, Roques BP, Carey RM: Conversion of renal angiotensin II to angiotensin III is critical for AT2 receptor-mediated natriuresis in rats. Hypertension 51: 460-465, 2008
9. Morice A, Pepke-Zaba J, Loysen E, Lapworth R, AshbyM, Higenbottam T, Brown M: Low dose infusion of atrial natriuretic peptide causes salt and water excretion in normal man. Clin Sci (Lond) 74: 359-363, 1988
10. Zhang MZ, Wang Y, Yao B, Gewin L, Wei S, Capdevila JH, Harris RC: Role of epoxyeicosatrienoic acids (EETs) in mediation of dopamine's effects in the kidney. Am J Physiol Renal Physiol 305: F1680-F1686, 2013
11. KohanDE: Role of collecting duct endothelin in control of renal function and blood pressure. Am J Physiol Regul Integr Comp Physiol 305: R659-R668, 2013
12. Nakano D, Pollock D: New concepts in endothelin control of sodium balance. Clin Exp Pharmacol Physiol 39: 104-110, 2012
13. Wilcox CS, Welch WJ: TGF and nitric oxide: Effects of salt intake and salt-sensitive hypertension. Kidney Int Suppl 55: S9-S13, 1996
14. Blaustein MP: Endogenous ouabain: Physiological activity and pathophysiological implications. Clin Investig 72: 706-707, 1994
15. Crambert S, Sjöberg A, Eklöf AC, Ibarra F, Holtbäck U: Prolactin and dopamine 1-like receptor interaction in renal proximal tubular cells. Am J Physiol Renal Physiol 299: F49-F54, 2010
16. Citarella MR, ChoiMR, GironacciMM, Medici C, Correa AH, Fernández BE: Urodilatin and dopamine: A new interaction in the kidney. Regul Pept 153: 19-24, 2009
17. Felder RA, Sanada H, Xu J, Yu PY, Wang Z, Watanabe H, Asico LD, Wang W, Zheng S, Yamaguchi I, Williams SM, Gainer J, Brown NJ, Hazen-Martin D,Wong LJ, Robillard JE, Carey RM, EisnerGM, Jose PA: G protein-coupled receptor kinase 4 gene variants in human essential hypertension. Proc Natl Acad Sci U S A 99: 3872-3877, 2002
18. Siragy HM, Felder RA, Howell NE, Chevalier RL, Peach MJ, Carey RM: Intrarenal dopamine acts at the dopamine-1 receptor to control renal function. J Hypertens Suppl 6: S479-S481, 1988
19. Hansell P, Fasching A: The effect of dopamine receptor blockade on natriuresis is dependent on the degree of hypervolemia. Kidney Int 39: 253-258, 1991
20. Chen CJ, Lokhandwala MF: Role of endogenous dopamine in the natriuretic response to various degrees of iso-osmotic volume expansion in rats. Clin Exp Hypertens A 13: 1117-1126, 1991
21. Bertorello A, Hökfelt T, GoldsteinM, Aperia A: Proximal tubuleNa+-K+-ATPase activity is inhibited during HS diet: Evidence for DA-mediated effect. Am J Physiol 254: F795-F801, 1988
22. Ragsdale NV, Lynd M, Chevalier RL, Felder RA, Peach MJ, Carey RM: Selective peripheral dopamine-1 receptor stimulation. Differential responses to sodiumloading and depletion in humans. Hypertension 15: 914-921, 1990
23. Meister B, Holgert H, Aperia A, Hökfelt T: Dopamine D1 receptor mRNA in rat kidney: Localization by in situ hybridization. Acta Physiol Scand 143: 447-449, 1991
24. Olsen NV, Olsen MH, Bonde J, Kanstrup IL, Plum I, Strandgaard S, Leyssac PP: Dopamine natriuresis in salt-repleted, water-loaded humans: A dose-response study. Br J Clin Pharmacol 43: 509-520, 1997
25. Cheng HF, Becker BN, Harris RC: Dopamine decreases expression of type-1 angiotensin II receptors in renal proximal tubule.JClinInvest 97: 2745-2752, 1996
26. Chen C, Lokhandwala MF: Potentiation by enalaprilat of fenoldopamevoked natriuresis is due to blockade of intrarenal production of angiotensin-II in rats. Naunyn Schmiedebergs Arch Pharmacol 352: 194-200, 1995
27. Luippold G, Zimmermann C, Mai M, Kloor D, Starck D, Gross G, Mühlbauer B: Dopamine D(3) receptors and salt-dependent hypertension. J Am Soc Nephrol 12: 2272-2279, 2001
28. Zeng C, Asico LD, Wang X, Hopfer U, Eisner GM, Felder RA, Jose PA: Angiotensin II regulation of AT1 and D3 dopamine receptors in renal proximal tubule cells of SHR. Hypertension 41: 724-729, 2003
29. Asico LD, Ladines C, Fuchs S, AcciliD, Carey RM, Semeraro C, Pocchiari F, Felder RA, Eisner GM, Jose PA: Disruption of the dopamine D3 receptor gene produces renin-dependent hypertension. J Clin Invest 102: 493-498, 1998
30. Choi MR, Lee BM, Medici C, Correa AH, Fernández BE: Effects of angiotensin II on renal dopamine metabolism: Synthesis, release, catabolism and turnover. Nephron, Physiol 115: 1-7, 2010
31. Gildea JJ,Wang X, Shah N, Tran H, Spinosa M, Van Sciver R, Sasaki M, Yatabe J, Carey RM, Jose PA, Felder RA: Dopamine and angiotensin type 2 receptors cooperatively inhibit sodium transport in human renal proximal tubule cells. Hypertension 60: 396-403, 2012
32. Padia SH, Kemp BA, Howell NL, Keller SR, Gildea JJ, Carey RM: Mechanisms of dopamine D(1) and angiotensin type 2 receptor interaction in natriuresis. Hypertension 59: 437-445, 2012
33. Sullivan JM: Salt sensitivity. Definition, conception, methodology, and long-term issues. Hypertension 17[Suppl]: I61-I68, 1991
34. Hughes JM, Beck TR, Rose CE Jr, Carey RM: Selective dopamine-1 receptor stimulation produces natriuresis by a direct tubular action. J Hypertens Suppl 4: S106-S108, 1986
35. Sanada H, Jones JE, Jose PA: Genetics of salt-sensitive hypertension. Curr Hypertens Rep 13: 55-66, 2011
36. Cook NR, Cutler JA, Obarzanek E, Buring JE, Rexrode KM, Kumanyika SK, Appel LJ, Whelton PK: Long term effects of dietary sodium reduction on cardiovascular disease outcomes: Observational follow-up of the trials of hypertension prevention (TOHP). BMJ 334: 885-888, 2007
37. Stolarz-Skrzypek K, Kuznetsova T, Thijs L, Tikhonoff V, Seidlerová J, Richart T, Jin Y, Olszanecka A, Malyutina S, Casiglia E, Filipovský J, Kawecka-Jaszcz K,Nikitin Y, Staessen JA; European Project onGenes in Hypertension (EPOGH) Investigators: Fatal and nonfatal outcomes, incidence of hypertension, and blood pressure changes in relation to urinary sodium excretion. JAMA 305: 1777-1785, 2011
38. Taylor AA, Shepherd AM, Polvino W, Mangoo-Karim R, Ballard K, Sunthornyothin S, Luther RR, Pool JL: Prolonged fenoldopam infusions in patients with mild to moderate hypertension: Pharmacodynamic and pharmacokinetic effects. Am J Hypertens 12: 906-914, 1999
39. Hughes JM, Ragsdale NV, Felder RA, Chevalier RL, King B, Carey RM: Diuresis and natriuresis during continuous dopamine-1 receptor stimulation. Hypertension 11: I69-I74, 1988
40. Elliott HL, Macdonald NJ, Meredith PA, Reid JL: Dose responses and pharmacokinetics for the angiotensin converting enzyme inhibitor quinapril. Clin Pharmacol Ther 51: 260-265, 1992
41. Burnier M, Monod ML, Chioléro A, Maillard M, Nussberger J, Brunner HR: Renal sodium handling in acute and chronic salt loading/depletion protocols: The confounding influence of acute water loading. J Hypertens 18: 1657-1664, 2000
42. Agnoli GC, Borgatti R, Cacciari M, Lenzi P, Marinelli M, Stipo L: Renal function and urinary prostanoid excretions in salt-depleted women: Comparative effects of enalapril and indomethacin treatments. Prostaglandins Leukot Essent Fatty Acids 60: 87-93, 1999
43. Zhang MZ, Yao B, Wang S, Fan X, Wu G, Yang H, Yin H, Yang S, Harris RC: Intrarenal dopamine deficiency leads to hypertension and decreased longevity in mice. J Clin Invest 121: 2845-2854, 2011
44. Grossman E, Hoffman A, Tamrat M, Armando I, Keiser HR, Goldstein DS: Endogenous dopa and dopamine responses to dietary salt loading in salt-sensitive rats. J Hypertens 9: 259-263, 1991
45. Jose PA, Felder RA, Holloway RR, Eisner GM: Dopamine receptors modulate sodium excretion in denervated kidney. Am J Physiol 250: F1033-F1038, 1986
46. Krishna GG, Danovitch GM, Beck FW, Sowers JR: Dopaminergic mediation of the natriuretic response to volume expansion. J Lab Clin Med 105: 214-218, 1985
47. Agnoli GC, Cacciari M, Garutti C, Ikonomu E, Lenzi P, Marchetti G: Effects of extracellular fluid volume changes on renal response to LSdose dopamine infusion in normal women. Clin Physiol 7: 465-479, 1987
48. Chobanian AV, Bakris GL, Black HR, CushmanWC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood PressureNational High Blood Pressure Education Program Coordinating Committee: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA 289: 2560-2572, 2003
49. Weder AB,Gleiberman L, Sachdeva A: Urinary dopamine excretion and renal responses to fenoldopam infusion in blacks and whites. J Clin Hypertens (Greenwich) 11: 707-712, 2009
50. O'Connell DP, Ragsdale NV, Boyd DG, Felder RA, Carey RM: Differential human renal tubular responses to dopamine type 1 receptor stimulation are determined by blood pressure status. Hypertension 29: 115-122, 1997
51. Bughi S, Horton R, Antonipillai I, Manoogian C, Ehrlich L, Nadler J: Comparison of dopamine and fenoldopam effects on renal blood flow and prostacyclin excretion in normal and essential hypertensive subjects. J Clin Endocrinol Metab 69: 1116-1121, 1989
52. Girbes AR, Smit AJ,Meijer S, ReitsmaWD: Renal and endocrine effects of fenoldopam andmetoclopramide in normalman. Nephron 56: 179-185, 1990
53. Murphy MB, McCoy CE, Weber RR, Frederickson ED, Douglas FL, Goldberg LI: Augmentation of renal blood flowand sodiumexcretion in hypertensive patients during blood pressure reduction by intravenous administration of the dopamine1 agonist fenoldopam. Circulation 76: 1312-1318, 1987
54. Mølstrøm S, Larsen NH, Simonsen JA, Washington R, Bie P: Normotensive sodium loading in normal man: Regulation of renin secretion during beta-receptor blockade. Am J Physiol Regul Integr Comp Physiol 296: R436-R445, 2009
55. Rasmussen MS, Simonsen JA, Sandgaard NC, Høilund-Carlsen PF, Bie P: Mechanisms of acute natriuresis in normal humans on low sodium diet. J Physiol 546: 591-603, 2003
56. Walter SJ, Sampson B, Shirley DG: A micropuncture study of renal tubular lithiumreabsorption in sodium-depleted rats. J Physiol 483: 473-479, 1995
57. Thomsen K, Shirley DG: The validity of lithium clearance as an index of sodium and water delivery from the proximal tubules. Nephron 77: 125-138, 1997
58. McDonough AA: Mechanisms of proximal tubule sodium transport regulation that link extracellular fluid volume and blood pressure. Am J Physiol Regul Integr Comp Physiol 298: R851-R861, 2010
59. DiBona GF: Physiology in perspective: The Wisdom of the Body. Neural control of the kidney. Am J Physiol Regul Integr Comp Physiol 289: R633-R641, 2005
60. Boer WH, Koomans HA, Dorhout Mees EJ, Gaillard CA, Rabelink AJ: Lithium clearance during variations in sodium intake in man: Effects of sodium restriction and amiloride. Eur J Clin Invest 18: 279-283, 1988
61. Wang X, Luo Y, Escano CS, Yang Z, Asico L, Li H, Jones JE, Armando I, Lu Q, Sibley DR, Eisner GM, Jose PA: Upregulation of renal sodium transporters in D5 dopamine receptor-deficient mice. Hypertension 55: 1431-1437, 2010
62. Jadhav AL, LokhandwalaMF: Dietary sodium-induced changes in renal noradrenergic and dopaminergic responses in rats. JHumHypertens 4: 163-164, 1990
63. Yoshimura M, Yamazaki H, Takashina R, Kambara S, Iyoda I, Sasaki S, Takahashi H, Takeda K, Ijichi H: The significance of duration of salt loading on cardiovascular response and urinary excretion of catecholamine in rats. Endocrinol Jpn 33: 169-175, 1986
64. McNabb WR, Noormohamed FH, Lant AF: The effects of enalapril on blood pressure and the kidney in normotensive subjects under altered sodium balance. J Hypertens 4: 39-47, 1986
65. Fransen R, BoerWH, Boer P, DorhoutMees EJ, Koomans HA: Effects of furosemide or acetazolamide infusion on renal handling of lithium: A micropuncture study in rats. Am J Physiol 264: R129-R134, 1993
66. Boer WH, Fransen R, Shirley DG, Walter SJ, Boer P, Koomans HA: Evaluation of the lithium clearance method: Direct analysis of tubular lithium handling by micropuncture. Kidney Int 47: 1023-1030, 1995
67. Lansang MC, Stevanovic R, Price DA, Laffel LM, Hollenberg NK: ACE and non-ACE pathways in the renal vascular response to RAS interruption in type 1 diabetes mellitus. Kidney Int 67: 1033-1037, 2005
68. van Brummelen P, Schalekamp M, de Graeff J: Influence of sodium intake on hydrochlorothiazide-induced changes in blood pressure, serum electrolytes, renin and aldosterone in essential hypertension. Acta Med Scand 204: 151-157, 1978
69. Bing RF, Thurston H, Swales JD: Salt intake and diuretic treatment of hypertension. Lancet 2: 121-123, 1979
70. Reinders A, Reggiori F, Shennan AH: Validation of the DINAMAP Pro-Care blood pressure device according to the international protocol in an adult population. Blood Press Monit 11: 293-296, 2006